Pharmaceutical Business Investment Opportunities

Company manufactures and sells nutraceutical products under its own brand name. - At present, we have 10 SKU's and gradually we are increasing with the demand. - Our registered office is in Delhi, India with its head office in Chandigarh. - We have a shop where we sell our products and also our own online website. - On average, we receive 100 orders per month. - We do sell our products to other offline retailers and through e-commerce websites like Amazon and Flipkart. - Products are all manufactured with the third party in the GMP facility and then branded by us. - Our revenue has grown exponentially due to the global scenario. - Our revenue generation is 50% from offline and 50% from online. - There are loans or debts taken by the company. - We are two directors who own 50% of the shares each.

Pharma marketing company and virtual manufacturer of nutraceuticals and generic pharma medicines. - Have 21 brands registered under our own name along with their trademarks. - Third-party manufacturing, all our products are WHO and GMP certified. - Mostly on-ground sales work where we visit hospitals, clinics, and onboard doctors to prescribe our products. - We have more than 50 doctors as our prescribers. - Strong distributor network in Delhi NCR, we have around 5 distributors. - Payment terms are negotiated with each client. - Business loan of INR 5 lakh is being repaid at the moment. - Two owners with equal shareholding. - Business had reached a pre-Covid revenue of INR 72 lakh. The company had exponential growth in the pre-Covid years. - Covid affected operations as we could not deploy our sales team to visit hospitals and clinics. - We are a fast-paced organization and wish to get this funding by the end of this financial year.

Our pharma company is recognized by Global Vegetarian, a Halal-certified company that also has brands registered in Kenya. - We get our products manufactured from a third party under our own brand name. - Product promotion and sales are done with the help of tie-ups with the doctors and currently, we have tie-ups with more than 50 doctors for the same. - Our revenue is increasing gradually with the recognition of the brand in the market. - The company is completely liabilities-free and is solely owned by the user only.

We are a pharma company established in Nepal and have a pharma wholesale unit. - The business has tie-ups with many wholesale and retail outlet. - Pharmaceutical industry in Nepal has been emerging as the best investment sector in the last few years. - We are planning to start our own manufacturing unit. The unit is not operational as of now. - The building and some machinery are ready. - We specialize in allopathic medicines. - Have more than 15 years of experience in this sector.

Updates on the business: The facility will have growing/extraction/distillation/packaging and R&D lab facilities in order to follow the entire stage of production from mother plants to crystallized forms of stand-alone cannabinoids. The intended R&D lab will be almost 200 sq. m. and will allow us to study lesser-known cannabinoids, and after the start of construction, we are going to sign the 'Partnership Joint Research' program with Athens University. Currently have signed a partnership agreement with a running pharmaceutical company on product supply + joint research program. Later on, we will focus on the distribution channels in each country of presence in order to be prepared to scale to the B2C market with potential own generic medicine and potentially edibles, but that will be decided by the market needs and legislation. We have received an installation license for such end products and as the project progresses we will add new products to the list: - Dried hemp flower > 0.2% THC in the form of teabag (tea bag) for oral consumption; - Hemp oil in drops for oral consumption > 0.2% THC; - Hemp oil for sublingual oral consumption (spray) > 0.2% THC; - Soft cannabis capsules for oral consumption > 0.2% THC; - Capsules with dried hemp blossom > 0.2% THC in powder form for oral consumption. At the moment we have: License and permits; Architectural and engineering plans; Purchase offers from equipment suppliers; All described production processes and laboratories; Long-term land lease for 30+ years with first an option of first to purchase it; Long-term lease and right of build on the neighboring land for the second stage of construction; The entire legal structure of the holding; Verification of processes and architectural solutions under EU GACP & EU GMP standards. By the end of last year have applied for the state subsidy of EUR 3.5mil and have the option to apply for the second state subsidy next year. Additionally, the project has a right for setting fixed corporate tax for the next 12 years. Overall the production facility is projected to grow 6.5+ tons of dried biomaterial (running at 70% capacity) on a single-tier growing table with the ability of scale and potential purchase of third-party biomaterial certified by GACP standards. The EU GMP Laboratory is projected to produce 2+ tons of fine oil with an option of scaling by putting a second processing line. Additionally, the project is built in mind with an option for a second-stage expansion through the building of an additional production site on the neighboring land.

Company manufactures generic pharmaceuticals for leading pharmaceutical companies. - Has more than 20 clients across Asia, Middle East, Africa and America. - Manufacturing capacity is 90,000 capsules per hour with latest equipment. Detailed capacities can be shared with interested parties upon introduction. - Company is established with an objective to provide unique product propositions which meets the customer requirements and expectations. - The unit is located at strategic location considering Gujarat a hub of various pharma giants. The existing manufacturing facility is equipped with latest technology for supreme manufacturing arrangement. - It has all valid license in terms of sales and export and approvals from WHO and FDA. - Company is a member of Pharmexcil (India) and Anti Microbial Resistance Industry Alliance (Switzerland). - The high growth in sales compared to last year is due to various factors including better economic situation with respect to the pandemic, increase number of approvals, capacity and clients. - Valuation is based on rapid growth rate and approvals. Company has applied for the European market approval which will open a door to new markets and client base. Company has the capacity to cater higher demands and requirements.

Our company developing and market potential pharmaceutical medicines that have no side effects. - The business has invested heavily in the research and development of anti-viral drugs. - Today, we have finished R&D and are ready to start production of a new drug that can help to prevent and treat many diseases including COVID-19. - The investment will be utilized to commence production and fulfil purchase orders from around the world.

We are an innovative company specialized in silicone development for healthcare and pharmaceutical area, established in 2009. We have been selling and exporting to many countries in Asia with our own patents and trade marks. The sales growing well each year so, when the sales increase the investment for funding support are needed. The reason for the loan is to support cash flow and stock inventory. Major products such as silicone gel for scar reduction, Asian formula, and silicone gel sheet for scars. Kelosil silicone gel plus CBD, we are the only one who can combine CBD (cannabidiol into silicone gel with transparent texture, which will a new evolution of silicone gel for wound healing and scar reductuion products. The new invention for cannabis (CBD) product development, we are brand owner of CBD products such as CBD cream, CBD drinks, Estimate Sales (year sales) 2022 = 44,000 USD. 2023 = USD 55,000. 2024 = USD 100,000. 2025 = USD 150,000. 2026 = USD 300,000.

We are a repackaging, distributing and marketing company for ayurvedic products and medicines. - We source various ayurvedic products from 50+ suppliers across India. Ayurvedic medicines are outsourced for manufacturing. All the products are sold under our brand name. - Majority of our products are sold to a high end wholesale business in Indore. Products are also sold via our e-commerce website across India. - Revenue is generated by selling the rebranded products. - The demand for our products is higher than the stock we can keep so we are expanding into manufacturing products. - The FSSAI and Ayush license has been granted. The manufacturing unit for this expansion is booked which is reflected in the high value of physical assets. - We can start the operations as soon as we receive capital. We expect the yearly sales to reach around INR 5 crore after we start manufacturing. - The owner has 6+ years of experience in this sector. - Investment stake will be provided for operations under this venture.

Nepal 1st Hormone and steroids based Pharmaceutical Company. -Hormones and steroids-based company with cleanroom, GMP certification, high tech equipment and a dedicated area for quality checks and innovation. - Fully Equipped for all Dosage form Solid and semisolid (Tablets, Capsule, ointment, liquid, cream, syrup soon on) - Major focused on innovation and creative drugs formulation and development. - We produce hormone medicines, generic tablets, liquids, ointments, capsules under our own brand name. - Have an in-house R&D department, quality control and quality assurance departments. - Currently have 14 hormone drugs and 18 general drugs and 60 new medicines are in the pipeline. - Business has over 55 distributors and super stockists who supply our drugs to doctors across Nepal. - We have enough production capacity to start exporting our medicines. - Huge Facility to start new project and plan. - Business is at the introductory phase of Product Life, with a better future perspective. - Facility is located in a safe place undisturbed with the residential area with good infrastructure and facilities. -Currently bearing losses due to first innovative products i. e. hormone manufacturers, facing many challenges from marketing and COVID pandemic crisis. - Secure future with innovative products in line along with huge production capacity and expansion possibilities. - The sales increased this year to ramping up of production and marketing efforts. The increase in revenue has taken our business to a break even point. We expect to be profitable in the upcoming year.